Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Research analysts at HC Wainwright lowered their FY2026 earnings estimates for Sagimet Biosciences in a report released on Friday, November 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($1.52) for the year, down from their previous estimate of ($1.31). HC Wainwright currently has a "Buy" rating and a $29.00 price target on the stock. The consensus estimate for Sagimet Biosciences' current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Sagimet Biosciences' Q4 2026 earnings at ($0.36) EPS, FY2027 earnings at ($1.29) EPS, FY2028 earnings at ($0.88) EPS and FY2029 earnings at $0.72 EPS.
Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.05).
Several other analysts have also recently issued reports on SGMT. Guggenheim boosted their price objective on shares of Sagimet Biosciences from $25.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, October 2nd. Citigroup restated a "market outperform" rating on shares of Sagimet Biosciences in a report on Friday. Wells Fargo & Company set a $27.00 target price on Sagimet Biosciences in a research report on Friday. Canaccord Genuity Group reduced their target price on Sagimet Biosciences from $56.00 to $50.00 and set a "buy" rating on the stock in a report on Friday. Finally, Citizens Jmp reduced their target price on Sagimet Biosciences from $29.00 to $27.00 and set a "market outperform" rating on the stock in a report on Thursday, October 1st. Nine investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $26.07.
Get Our Latest Stock Analysis on Sagimet Biosciences
Sagimet Biosciences Stock Down 0.9%
NASDAQ:SGMT opened at $10.13 on Tuesday. The company has a market cap of $629.68 million, a P/E ratio of -8.51 and a beta of 3.43. Sagimet Biosciences has a fifty-two week low of $4.50 and a fifty-two week high of $11.45. The firm's 50 day moving average is $9.86 and its two-hundred day moving average is $7.71.
Institutional Investors Weigh In On Sagimet Biosciences
Institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. raised its stake in shares of Sagimet Biosciences by 15.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,238 shares of the company's stock valued at $105,000 after acquiring an additional 1,500 shares during the period. Baird Financial Group Inc. boosted its position in Sagimet Biosciences by 19.8% during the 2nd quarter. Baird Financial Group Inc. now owns 15,677 shares of the company's stock worth $121,000 after purchasing an additional 2,591 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Sagimet Biosciences during the 3rd quarter worth $31,000. Fulcrum Asset Management LLP acquired a new stake in Sagimet Biosciences in the 3rd quarter valued at $37,000. Finally, Profund Advisors LLC increased its holdings in Sagimet Biosciences by 36.1% in the 3rd quarter. Profund Advisors LLC now owns 19,737 shares of the company's stock valued at $195,000 after purchasing an additional 5,234 shares in the last quarter. 87.86% of the stock is currently owned by hedge funds and other institutional investors.
Latest Sagimet Biosciences News
Here's some of the latest news about SGMT:
About Sagimet Biosciences
(
Get Free Report)
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body's production of fatty acids. The company is based in San Mateo, California. Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions. Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sagimet Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sagimet Biosciences wasn't on the list.
While Sagimet Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.